The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
An assessment of disease features and immune response in breast cancer patients that did not recur after receiving HER2 peptide, AE37 vaccine in a randomized phase II trial.
Diane F Hale
No relevant relationships to disclose
Sonia A. Perez
No relevant relationships to disclose
Timothy J Vreeland
No relevant relationships to disclose
Alfred F Trappey
No relevant relationships to disclose
Raetasha Sheavette Dabney
No relevant relationships to disclose
John S. Berry
No relevant relationships to disclose
Alexandros Ardavanis
No relevant relationships to disclose
Alan K. Sears
No relevant relationships to disclose
Michael Papamichail
No relevant relationships to disclose
Guy T. Clifton
No relevant relationships to disclose
Efi Pappou
No relevant relationships to disclose
Ritesh Patil
No relevant relationships to disclose
Eleftheria Anastasopoulou
No relevant relationships to disclose
Sathibalan Ponniah
No relevant relationships to disclose
Nathan M. Shumway
No relevant relationships to disclose
George Earl Peoples
Consultant or Advisory Role - Advisory Role; Antigen Express (U); Owns IP pertaining to AE37 vaccine
Research Funding - Antigen Express; Funding of Current Clinical Trial
Elizabeth Ann Mittendorf
No relevant relationships to disclose